Cetuximab–platinum chemotherapy is used for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC); however, a minority of patients benefit. Gene expression profiling (GEP) of HNSCCs with prolonged responses to cetuximab-chemotherapy demonstrate basal subtype traits including signatures of EGFR signaling and hypoxic differentiation. GEP of short-response patients show RAS activation. Clin Cancer Res; 22(15); 3710–2. ©2016 AACR.
See related article by Bossi et al., p. 3961
- Received March 22, 2016.
- Accepted March 23, 2016.
- ©2016 American Association for Cancer Research.